6.435
price up icon1.82%   0.115
after-market 시간 외 거래: 6.40 -0.035 -0.54%
loading

Prothena Corporation Plc 주식(PRTA)의 최신 뉴스

pulisher
Jun 18, 2025

Prothena announces 63% workforce reduction following birtamimab halt - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (PRTA) Cuts Workforce by 63% to Reduce Costs - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (PRTA) Shares Rise Following Corporate Restructuring an - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena Announces Major Workforce Reduction to Cut Costs - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (PRTA) Adjusts 2025 Financial Outlook Amid Reorganizati - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena Announces Corporate Restructuring | PRTA Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (PRTA) Announces Leadership Changes Amid Workforce Reduction | PRTA Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena to cut workforce by 63% amid strategic review - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena announces corporate restructuring - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena Announces Corporate Restructuring - Business Wire

Jun 18, 2025
pulisher
Jun 18, 2025

Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (NASDAQ:PRTA) Shares Pass Below 200 Day Moving Average – Time to Sell? - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) - Insider Monkey

Jun 17, 2025
pulisher
Jun 16, 2025

(PRTA) Trading Signals - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Financial Analysis: Prothena Corporation plc (PRTA)’s Ratios Unveil Key Insights - DWinneX

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena stock rises on Parkinson's trial update (PRTA:NASDAQ) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena’s Prasinezumab Advances to Phase III for Parkinson’s - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena partner Roche advances Parkinson’s drug to phase 3 By Investing.com - Investing.com Nigeria

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena's Partner Roche to Advance Prasinezumab into Phase III - GuruFocus

Jun 16, 2025
pulisher
Jun 14, 2025

Prothena’s SWOT analysis: stock faces challenges after trial setback By Investing.com - Investing.com South Africa

Jun 14, 2025
pulisher
Jun 14, 2025

Prothena’s SWOT analysis: stock faces challenges after trial setback - Investing.com

Jun 14, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts Prothena FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Two Sigma Investments LP Buys 27,887 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Prothena Co. plc (NASDAQ:PRTA) Short Interest Update - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Bank of America Corp DE Purchases 36,944 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

(PRTA) Technical Data - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 03, 2025

Millennium Management LLC Has $1.70 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

PROTHENA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Prothena Corporation plc To Contact The Firm - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 02, 2025

ProShare Advisors LLC Buys 3,312 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World

Jun 02, 2025
pulisher
May 31, 2025

Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN

May 31, 2025
pulisher
May 31, 2025

Prothena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

May 31, 2025
pulisher
May 31, 2025

Chardan Capital Decreases Earnings Estimates for Prothena - Defense World

May 31, 2025
pulisher
May 30, 2025

Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails - MSN

May 30, 2025
pulisher
May 30, 2025

H.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PT - Insider Monkey

May 30, 2025
pulisher
May 30, 2025

FY2027 EPS Estimates for Prothena Decreased by HC Wainwright - Defense World

May 30, 2025
pulisher
May 30, 2025

Prothena (NASDAQ:PRTA) Given “Underperform” Rating at Bank of America - Defense World

May 30, 2025
pulisher
May 29, 2025

Bank of America Reiterates “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World

May 29, 2025
pulisher
May 29, 2025

Bank of America Reaffirms “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World

May 29, 2025
pulisher
May 29, 2025

Prothena (NASDAQ:PRTA) Receives Underperform Rating from Bank of America - Defense World

May 29, 2025
pulisher
May 29, 2025

The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts - simplywall.st

May 29, 2025
pulisher
May 29, 2025

BofA cuts Prothena stock rating, slashes target to $4 By Investing.com - Investing.com Nigeria

May 29, 2025
pulisher
May 28, 2025

Prothena Corp (PRTA) Sees Downgrade and Price Target Cut by B of A Securities | PRTA Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform - Insider Monkey

May 28, 2025
pulisher
May 28, 2025

BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | P - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | PRTA Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down - MSN

May 28, 2025
pulisher
May 28, 2025

Prothena (PRTA) Downgraded by BofA Analyst with Lower Price Targ - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Prothena (NASDAQ:PRTA) Price Target Lowered to $81.00 at Piper Sandler - Defense World

May 28, 2025
pulisher
May 28, 2025

Prothena (NASDAQ:PRTA) Price Target Cut to $29.00 by Analysts at JMP Securities - Defense World

May 28, 2025
pulisher
May 28, 2025

Prothena (NASDAQ:PRTA) Lowered to Hold Rating by Jefferies Financial Group - Defense World

May 28, 2025
pulisher
May 28, 2025

Prothena (NASDAQ:PRTA) Given New $14.00 Price Target at HC Wainwright - Defense World

May 28, 2025
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
자본화:     |  볼륨(24시간):